Our Mission

Genetic Immunity is a company focused on establishing leadership in Nanomedicines for immune amplification.

 

Our Company

Genetic Immunity has leveraged its immune amplification platform technology to develop the DermaVir Patch, its lead nanomedicine candidate in Phase II development for HIV/AIDS. Based on the Company's NanoComp nanoparticle composition platform and its DermaPrep delivery system, the plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the immune system to kill only HIV-infected cells.

DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific T cells.

>> Genetic Immunity in the News...

 
>>Active HIV/AIDS program...

DermaVir Patch

>> Latest News...
07.13.2008Genetic Immunity to Present at 2008 BIO International Convention
04.21.2008Full viral suppression newest trend seen in the "post-HAART" era
04.18.2008GI Published Data Related to the DermaVir NanomMedicine Patch in the Journal of Immunology
 

Site MapLast Update: July 17, 2008